Member Info for David1951c

Have followed MXCT for some time and SP looks attractive when considering the large fund raise in 2021 and large cash holding. I didn't understand why they needed to raise so much but investors must see medium - long term value. SP has dropped by over 60% from last year's high. Bought 2000 at 442p to dip toe into the water.

Key question for me is funding. With longer project timescales and higher costs, will there need to be a fund raise and would it involve dilution? Still hoping that partnership with Wood could be crowned with issue of shares to them at a sensible price to say take a 10%-15% shareholding. Both parties would benefit as SP will rise in 2022/23 if the project pipeline can be progressed and more plants come on stream.
Other question is commissioning risks on new plants. When was the last one completed and operational?

From The Times today and why the work in P3 could mean DEST have an important role within a few years to deal with AMR in numerous areas including wound infection.
Superbugs resistant to antibiotics are now a leading cause of death worldwide and claimed 1.3 million lives in 2019, a study has found.
Antimicrobial resistance (AMR) kills more people than HIV and Aids or malaria, researchers said. There were more than 51,000 deaths in western Europe in 2019.
Chris Murray, a co-author of the study, from the Institute for Health Metrics and Evaluation at the University of Washington, said: “Previous estimates had predicted ten million annual deaths from antimicrobial resistance by 2050, but we now know for certain that we are already far closer to that figure than we thought.” He called for the data to “drive innovation if we want to stay ahead in the race against antimicrobial resistance”.
The deaths occur when common infections, such as a urinary tract infection or infected wound, can no longer be treated because the bacteria that cause them have become resistant.

As a minor PI I believe all companies should issue half year and year end updates within 30 days of the close of each period especially when there is a lot going on. ORPH have RNSd numerous contract wins which mention amounts but it is not easy to work out what that means in timing of the revenue into the accounts. They should be able to issue a y/e update in January to confirm the estimated 2021 revenue of £40m has been achieved and if in a positive EBITA position. Also they should be able to give an updated projection for 2022 last mentioned in half year report. PIs would find this helpful and encourage more investors.
I have only 60k shares having sold some at nearly 30p, on almost a free carry but will add when SP stops decline.

Option for everyone given the vagaries of AIM and the SP plunge e.g. in such as NCYT and Avacta from highs down by around 70%. It actually makes sense in most cases as part of risk management. Of course SP may drop and then buy back in.
Agee with Skippy that if it gets to £5 selling part is an option but depends on circumstances at that time. In my case I may sell 20% and have rest on a free carry.

Very encouraging update and DEST is moving forward on all fronts. Having two P3 in next 12 months is particularly significant with progress in other areas too. Key issue is quality and terms of partnerships to progress P3 trials. SP action is muted but the potential remains huge and is not so far away.

Wood are giving an update tomorrow for y/e 31.12.2021 so will be interesting to see anything on EQT. It is only nearly two months since the announcement so not expecting much in way of concrete steps. Hopefully the joint team are working hard to develop the next steps and specific projects.
To seal the collaboration it would be good if Wood take an equity stake through issue of shares - say 1000m at 1.50p to raise £15m for driving progress in the large pipeline of projects. With the expected (and hoped for) SP rise that investment could easily double in the next two years. Wishful thinking maybe!

What PXEN need to do is get the issues at Selva sorted out so first gas can come in time for next winter (Q4). If there is a crisis then a more ambitious resolution should be sought.

I first invested in SNG well before Covid because of potential with treating COPD. According to British Lung Foundation 1.2m people in UK live with COPD with 114,000 new cases per year. The potential for COPD worldwide is big and adding Covid treatment means the potential is huge. With the trial being conducted in multiple countries the benefits would be recognised on a wide scale if the outcome is successful as we all hope,

In August we were told (RNS) that JR was scheduled for early December but cannot see any more recent timings. Couldn't see anything recent on GLP website either.
Hope ABDX will provide update in next announcement.

Huge potential!
Is there any information on capacity and production ramp up - how many tests can Medusa 19 produce per month?
Medusa website not yet updated?

Bought 250k more at 1.275 also shown as a sell. Not unusual but suggests a pattern of sells which might influence others to sell.

H2 Energy Solutions is a new company formed a year ago so this will take time to develop but Germany should be a key market as the new coalition government includes the Green Party and there are clear federal objectives for climate change actions. Also Germany has a much bigger industrial base and need to deal with waste with a reduction in incineration. Still patience required but suggests H2 also see the value EQT can bring in a competitive market. Bought 500k more shares at 1.30 shown as a sell on LSE.

Boo could issue a TU for three months ending 30 November (instead of four months to end December) to put investors' minds at rest with regard to sales revenue and margins etc. The steady and significant SP decline requires something from the company to halt the drop.

Trek,
Helpful and positive comments as always!
I am not sure why RNS today has lead to more sells than buys especially with another announcement due in 2-3 weeks with more contract completions. I can only assume that some sellers are disappointed the SP has not moved up materially and impatiently look for more immediate gains. Of course we would all like to see a concerted and sustained rise but that may only happen if there is significantly more interest from new and existing IIs.
As usual there is little in the way of concrete revenue numbers and we may have to wait until interims in about two months time. That should confirm that revenue is rising to cover all costs.
It would also help if the £1.7m revenue not recognised is collected at least in part.
Re-reading the very detailed 2 November RNS confirms the company is building it's position as market leader and there are actions to unlock the huge potential. Hoping that CY 2022 will be a year of significant growth including early lung that will drive SP over the previous high. I have kept 40k shares but won't add until even more progress is achieved.
Still wonder if this could be a take over target but that may be wishful thinking.

aandi - you are a regular poster and very strong supporter of EQT. You set out many important and relevant points on most aspects and try to address concerns in a constructive and positive way which is reassuring. There is a huge amount going on and I believe the company will succeed and the Mcap will go much higher. However there may be bumps on the way. Although the cash position on 30 June is clear, in my view an equity fund raise cannot be ruled out if the company is to meet their significant ambitions. We need to see financial close of more projects or at least TP commitments to funding and if the revenue target for y/e is not met there will likely be more sellers. How can you explain the much higher sells today after what appears to be positive news? Why is there not more institutional buying?
As a holder for a number of years and with over 4m shares, I care about the company, follow the announcements and presentations etc. However, I will not buy more shares until the progress is more concrete in financial terms.
I was very pleased with the Wood collaboration and this could accelerate development. As they are big in UK perhaps they can add weight to Deeside progressing more quickly. Of course their USA presence could make a huge difference there.
Patience is needed but the SP fluctuation is frustrating.

Been hoping for this for months! Wood are an excellent partner and big in the biggest market USA. This should really get developments and expansion moving more quickly and into more new markets. Really need to get a few projects completed and running to showcase the tech. Wood should also be able to assist with any commissioning risks of new plants where resources will be needed.
On SP we are all hoping for a sustained rise and when some sellers are out of the way it may happen. It would be good to have institutional investors taking up the slack. Perhaps Wood will build a modest stake at these prices. If additional funding is need to speed up developments, perhaps Wood will take an equity stake through the issue of more shares at a good price.
Lots to look forward to!

It is more than 4 months since last operational update. For some reason BMV want to take six months to issue a prospectus when they've done two in recent years and cannot even get a new website done in four months. As a shareholder for more than three years I feel the company are treating me poorly in not making faster progress. Although they have skin in the game the top brass don't seem too bothered or at least can't be bothered.

Might their strategic review announced today have a possible collaboration with EQT?

Good to see more activity today and SP rise. News on partnership for M3 due soon for Phase 3 to start in H1 2022.